37 stories mentioning BIIB
Every FINWIRES story that references BIIB, newest first.
Biogen (BIIB) has an average rating of overweight and mean price target of $219.86, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Healthcare stocks were rising premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 1.5% higher and the iShares Biotechnology ETF (IBB) advancing by 0.6%.Biogen (BIIB) shares were up more than 1% after the company said the US Food and Drug Administration has granted breakthrough therapy designation for Salanersen to treat spinal muscular atrophy, a rare, genetic and neuromuscular disease.Royal Philips (PHG) and WellSpan Health said they have entered into a seven-year partnership focused on research, innovation, and the deployment of advanced imaging and diagnostic technologies across WellSpan's network. Shares of Royal Philips were up more than 1% pre-bell.Amneal Pharmaceuticals (AMRX) stock was 1% higher after the company said has received the US Food and Drug Administration's approval for its romidepsin injection solution.
Healthcare stocks were rising premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 1.5% higher and the iShares Biotechnology ETF (IBB) advancing by 0.6%.Biogen (BIIB) shares were up more than 1% after the company said the US Food and Drug Administration has granted breakthrough therapy designation for Salanersen to treat spinal muscular atrophy, a rare, genetic and neuromuscular disease.
Health care stocks were mixed premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.6% higher and the iShares Biotechnology ETF (IBB) down 0.1%.Biogen (BIIB) and Denali Therapeutics (DNLI) are discontinuing further development of BIIB122 in idiopathic Parkinson's disease after a phase 2b study failed to meet its primary or secondary endpoints, the companies said. Biogen shares were down 1% and Denali Therapeutics stock lost more than 3% pre-bell.Medline (MDLN) shares were up more than 1% after the company priced its upsized secondary offering of about 72.6 million of its class A shares on behalf of certain selling stockholders at $37 apiece.Gilead Sciences (GILD) said the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion supporting approval of Trodelvy as a first-line treatment for certain patients with metastatic triple-negative breast cancer. Gilead Sciences shares were 0.4% higher pre-bell.
Health care stocks were mixed premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.5% higher and the iShares Biotechnology ETF (IBB) down 0.1%.Biogen (BIIB) and Denali Therapeutics (DNLI) are discontinuing further development of BIIB122 in idiopathic Parkinson's disease after a phase 2b study failed to meet its primary or secondary endpoints, the companies said. Biogen shares were down 1% and Denali Therapeutics stock lost more than 3% pre-bell.
US equity indexes ended higher on Thursday as technology stocks led major gains in the Nasdaq and the S&P 500, pushing them toward new all-time highs.* Among the top 10 companies with a market capitalization of more than $200 billion, implying a significant sway over indexes, eight were from the technology sector. In the S&P 500 and Nasdaq, Cisco Systems (CSCO) was the top outperformer.* Retail sales in April rose for the third straight month, up 0.5% following a revised 1.6% gain in March, the Census Bureau reported Thursday, matching the consensus in a survey compiled by Bloomberg.* June West Texas Intermediate crude oil rose $0.81 to settle at $101.83 per barrel, while July Brent crude, the global benchmark, was last seen up $0.74 at $106.37.* Cisco (CSCO) shares were up roughly 13% after the company reported a year-over-year rise in fiscal Q3 earnings and revenue, beating market expectations, and raised its fiscal 2026 guidance. The firm also announced restructuring plans that included lay-offs of nearly 4,000 employees.* Biogen (BIIB) shares were down 6.4% after the company said a phase 2 trial of diranersen in people with early Alzheimer's disease did not meet its primary endpoint.
Healthcare stocks were mixed late Thursday afternoon, with the NYSE Healthcare Index easing 0.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) fractionally higher.The iShares Biotechnology ETF (IBB) decreased 0.7%.In corporate news, Prestige Consumer Healthcare's (PBH) officials said Thursday that weak eye care sales and a difficult consumer backdrop drove disappointing fiscal Q4 results at the consumer healthcare products company. Its shares were down past 11%.Biogen (BIIB) shares fell nearly 7% after the firm said Thursday that a phase 2 trial of diranersen in people with early Alzheimer's disease did not meet its primary endpoint.Doximity (DOCS) could face near-term pressure from slowing growth after issuing weaker-than-expected guidance, though strong user engagement trends and expanding AI opportunities continue to support the stock's long-term outlook, Morgan Stanley said in a note. Morgan Stanley lowered the price target on Doximity to $35 from $49, while maintaining an overweight rating. Doximity shares dropped more than 23%.Aveanna Healthcare (AVAH) shares jumped past 8% after it reported higher fiscal Q1 adjusted earnings and revenue, and raised its fiscal 2026 revenue guidance.
Healthcare stocks edged down Thursday afternoon, with the NYSE Healthcare Index easing 0.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) fractionally lower.The iShares Biotechnology ETF (IBB) decreased 0.5%.In corporate news, Biogen (BIIB) shares fell nearly 6% after the firm said Thursday that a phase 2 trial of diranersen in people with early Alzheimer's disease did not meet its primary endpoint.Prestige Consumer Healthcare (PBH) reported weaker-than-expected Q4 results and issued 2026 guidance below consensus, with the shortfall driven primarily by supply constraints in Clear Eyes and broader execution pressures, Oppenheimer said in a note. Oppenheimer downgraded the stock to perform from outperform and removed its $65 price target. Prestige shares slumped past 8%.Doximity (DOCS) could face near-term pressure from slowing growth after issuing weaker-than-expected guidance, though strong user engagement trends and expanding AI opportunities continue to support the stock's long-term outlook, Morgan Stanley said in a note. Morgan Stanley lowered the price target on Doximity to $35 from $49, while maintaining an overweight rating. Doximity shares dropped more than 24%.Aveanna Healthcare (AVAH) shares jumped 11% after it reported higher fiscal Q1 adjusted earnings and revenue, and raised its fiscal 2026 revenue guidance.
Healthcare stocks edged down Thursday afternoon, with the NYSE Healthcare Index easing 0.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) fractionally lower.The iShares Biotechnology ETF (IBB) decreased 0.6%.In corporate news, Biogen (BIIB) shares fell about 5% after the firm said Thursday that a phase 2 trial of diranersen in people with early Alzheimer's disease did not meet its primary endpoint.
Biogen (BIIB) has an average rating of overweight and mean price target of $0, according to analysts polled by FactSet.Price: $194.50, Change: $-10.03, Percent Change: -4.90%
Biogen (BIIB) still appears likely to secure approval for the subcutaneous induction version of Alzheimer's drug "Leqembi" despite a delayed US Food and Drug Administration review, with recent regulatory precedents and existing clinical data supporting a favorable outcome, RBC Capital Markets said in a report Thursday.Regulators may need more time to assess safety aspects of the filing, particularly the risk of Amyloid-Related Imaging Abnormalities-Edema/Effusion, or ARIA-E events, in treatment-naive patients. Still, Leqembi's subcutaneous maintenance version is already approved and the data has effectively been under FDA review for about seven months.The filing relies on pharmacokinetic and pharmacodynamic, or PK/PD, modeling showing that a 500 mg weekly subcutaneous dose should produce results similar to the approved intravenous version, RBC said, adding that past cases involving non-Chemistry, Manufacturing and Controls FDA review delays have generally resulted in eventual approvals, even though there is no exact precedent for Leqembi's specific situation.RBC has an outperform rating on Biogen, with a price target of $222.Shares of Biogen were down more than 5% in Thursday trading.Price: $194.19, Change: $-10.34, Percent Change: -5.06%
All three major US stock indexes were up in late-morning trading Thursday, as investors monitor news emanating from President Donald Trump's meeting with Chinese President Xi Jinping in Beijing.In company news, Cisco Systems (CSCO) reported fiscal Q3 adjusted earnings late Wednesday of $1.06 per diluted share, up from $0.96 a year earlier and above the FactSet consensus analyst estimate of $1.03. Fiscal Q3 revenue was $15.8 billion, up from $14.1 billion a year ago and above the FactSet consensus of $15.6 billion. For fiscal Q4, Cisco said it expects Q4 adjusted EPS of $1.16 to $1.18 on revenue of $16.7 billion to $16.9 billion. Analysts polled by FactSet expect $1.08 and $15.8 billion, respectively. Cisco shares were up 15.0% around midday.Alibaba (BABA) and JD.com (JD) are among the roughly 10 Chinese companies that have secured US clearance to buy Nvidia's (NVDA) H200 artificial intelligence chips, though no deliveries have been made yet, Reuters reported Thursday, citing three people familiar with the matter. Alibaba and JD shares were down 1.9% and 2.1%, respectively. Nvidia shares were up 4.6%.Chinese President Xi Jinping told the chief executives of Apple (AAPL), Tesla (TSLA), Nvidia and other large companies that China will "open wider" to doing business, CNBC reported Thursday, citing a report from state-backed newspaper Xinhua. Apple shares were up 0.1%, while Tesla shares were up 0.8%.Biogen (BIIB) said Thursday that a phase 2 study evaluating diranersen in patients with early Alzheimer's disease did not meet its primary endpoint evaluating dose response for change from baseline on the Clinical Dementia Rating-Sum of Boxes at Week 76. Biogen shares were down 5.0%.Price: $117.40, Change: $+15.53, Percent Change: +15.24%
Healthcare stocks were mixed premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.2% higher and the iShares Biotechnology ETF (IBB) declining by 0.1%.Aveanna Healthcare (AVAH) stock was up more than 9% after the company reported higher fiscal Q1 adjusted earnings and revenue, and raised its fiscal 2026 revenue guidance.Biogen (BIIB) shares were up more than 1% after the company said a phase 2 study evaluating diranersen in patients with early Alzheimer's disease did not meet its primary endpoint evaluating dose response for change from baseline on the Clinical Dementia Rating-Sum of Boxes at week 76.MeiraGTx (MGTX) stock was down 1% after the company posted a wider Q1 adjusted loss as revenue fell during the period.
Biogen (BIIB) has an average rating of overweight and mean price target of $0, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $188.65, Change: $-0.63, Percent Change: -0.33%
Biogen (BIIB) has an average rating of overweight and mean price target of $215.86, according to analysts polled by FactSet.Price: $191.43, Change: $-2.95, Percent Change: -1.52%
Biogen (BIIB) has an average rating of overweight and mean price target of $215.86, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $191.38, Change: $-3.00, Percent Change: -1.54%
Biogen (BIIB) has an average rating of overweight and mean price target of $215.86, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $191.77, Change: $-2.61, Percent Change: -1.34%
Biogen (BIIB) has an average rating of overweight and mean price target of $215.86, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $191.77, Change: $-2.61, Percent Change: -1.34%
Biogen (BIIB) has an average rating of overweight and mean price target of $215.86, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $191.38, Change: $-3.00, Percent Change: -1.54%
Biogen (BIIB) has an average rating of overweight and mean price target of $215.86, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $191.38, Change: $-3.00, Percent Change: -1.54%
Showing 1-20 of 37